Sacubitril-valsartan in heart failure: Why are more physicians not prescribing it?

Annals of Internal Medicine

Volumn 165, Issue 10, 2016, Pages 735-736

  Packer, Milton ^a   Mark Armstrong, W ^b   Rothstein, Joseph M ^b   Emmett, Michael ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; LOSARTAN; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE;

CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEART FAILURE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

AMINOBUTYRATES; HEART FAILURE; HUMANS; TETRAZOLES;

EID: 84995973146     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1932     Document Type: Editorial

References (10)

1. Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016;165: 681-9. doi:10.7326/M16-0057
2. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Costeffectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4:392-402. [PMID: 27039128] doi:10 .1016/j.jchf.2016.02.007
3. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016. [PMID: 27438344] doi:10.1001/jamacardio.2016.1747
4. Packer M. Love of angiotensin-converting enzyme inhibitors in the time of cholera. JACC Heart Fail. 2016. [PMID: 27107555] doi:10 .1016/j.jchf.2016.02.012
5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016. [PMID: 27208050]
6. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61. [PMID: 25403646] doi:10.1161/CIRCULATIONAHA.114.013748
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. [PMID: 25176015] doi:10.1056/NEJMoa1409077
8. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016. [PMID: 27395349] doi:10.1016/j.jchf.2016.05.002
9. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990-7. [PMID: 26022006] doi:10.1093/eurheartj/ehv186
10. Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, et al; PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan [Letter]. N Engl J Med. 2015;373:2289-90. [PMID: 26630151] doi:10.1056/NEJMc1509753